Literature DB >> 19217168

Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination.

Rachel E Maddux1, Lawrence P Riso, Daniel N Klein, John C Markowitz, Barbara O Rothbaum, Bruce A Arnow, Rachel Manber, Janice A Blalock, Gabor I Keitner, Michael E Thase.   

Abstract

BACKGROUND: Individuals with chronic depression respond poorly to both medication and psychotherapy. The reasons for the poorer response, however, remain unclear. One potential factor is the presence of comorbid Axis II personality disorders (PDs), which occur at high rates among these patients.
METHODS: This study examines the moderating influence of co-occurring PDs, primarily in cluster C, among 681 chronically depressed adult outpatients who were randomly assigned to 12 weeks of treatment with nefazodone, a specialized psychotherapy for chronic depression, or their combination.
RESULTS: At baseline, 50.4% (n=343) of patients met criteria for one or more Axis II disorders. Following 12 weeks of treatment, patients with comorbid PDs had statistically lower depression scores (M=12.2, SD=+9.2) than patients without comorbid PDs (M=13.5, SD=+8.7). There was no differential impact of a comorbid PD on responsiveness to medication versus psychotherapy. The results did not change when the data were analyzed using an intent-to-treat sample or when individual personality disorders were examined separately. LIMITATIONS: Patients with severe borderline, antisocial, and schizotypal PDs were excluded from study entry; therefore, these data primarily apply to patients with cluster C PDs and may not generalize to other Axis II conditions.
CONCLUSIONS: Comorbid Axis II disorders did not negatively affect treatment outcome and did not differentially affect response to psychotherapy versus medication. Treatment formulations for chronically depressed patients with certain PDs may not need to differ from treatment formulations of chronically depressed patients without co-occurring PDs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19217168     DOI: 10.1016/j.jad.2009.01.010

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  10 in total

1.  The role of personality pathology in depression treatment outcome with psychotherapy and pharmacotherapy.

Authors:  Jessica C Levenson; Meredith L Wallace; Jay C Fournier; Paola Rucci; Ellen Frank
Journal:  J Consult Clin Psychol       Date:  2012-07-23

Review 2.  A review of empirically supported psychological therapies for mood disorders in adults.

Authors:  Steven D Hollon; Kathryn Ponniah
Journal:  Depress Anxiety       Date:  2010-10       Impact factor: 6.505

Review 3.  Personalized medicine for depression: can we match patients with treatments?

Authors:  Gregory E Simon; Roy H Perlis
Journal:  Am J Psychiatry       Date:  2010-09-15       Impact factor: 18.112

4.  Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings from the EMBARC Study.

Authors:  Jay C Fournier; Henry W Chase; Tsafrir Greenberg; Amit Etkin; Jorge R Almeida; Richelle Stiffler; Thilo Deckersbach; Sarah Weyandt; Crystal Cooper; Marisa Toups; Tom Carmody; Benji Kurian; Scott Peltier; Phillip Adams; Melvin G McInnis; Maria A Oquendo; Patrick J McGrath; Maurizio Fava; Myrna Weissman; Ramin Parsey; Madhukar H Trivedi; Mary L Phillips
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-12-06

5.  Predictors of treatment outcomes among depressed women with childhood sexual abuse histories.

Authors:  Natalie A Cort; Stephanie A Gamble; Phillip N Smith; Linda H Chaudron; Naiji Lu; Hua He; Nancy L Talbot
Journal:  Depress Anxiety       Date:  2012-05-08       Impact factor: 6.505

6.  Personality features, dissociation, self-stigma, hope, and the complex treatment of depressive disorder.

Authors:  Jan Prasko; Marie Ociskova; Ales Grambal; Zuzana Sigmundova; Petra Kasalova; Marketa Marackova; Michaela Holubova; Kristyna Vrbova; Klara Latalova; Milos Slepecky
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-07       Impact factor: 2.570

Review 7.  Neural Implications of Psychotherapy, Pharmacotherapy, and Combined Treatment in Major Depressive Disorder.

Authors:  Thomas L Schwartz; Daniel Santarsieri
Journal:  Mens Sana Monogr       Date:  2016 Jan-Dec

8.  Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders.

Authors:  Jan Prasko; Ales Grambal; Petra Kasalova; Dana Kamardova; Marie Ociskova; Michaela Holubova; Kristyna Vrbova; Zuzana Sigmundova; Klara Latalova; Milos Slepecky; Marta Zatkova
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-17       Impact factor: 2.570

9.  Borderline Personality Features in Patients With Persistent Depressive Disorder and Their Effect on CBASP Outcome.

Authors:  Franziska Konvalin; Fabienne Grosse-Wentrup; Tabea Nenov-Matt; Kai Fischer; Barbara B Barton; Stephan Goerigk; Eva-Lotta Brakemeier; Richard Musil; Andrea Jobst; Frank Padberg; Matthias A Reinhard
Journal:  Front Psychiatry       Date:  2021-03-12       Impact factor: 4.157

10.  Mood and Global Symptom Changes among Psychotherapy Clients with Depressive Personality.

Authors:  Rachel E Maddux; Lars-Gunnar Lundh
Journal:  Depress Res Treat       Date:  2012-12-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.